Natera stock trades steady as genetic testing growth supports recent earnings

Natera stock, tied to the molecular diagnostics specialist Natera Inc. (ISIN US6323071042), represents exposure to a business built around genetic testing for oncology and women’s health. The company’s most recent reported quarterly figures showed double digit revenue growth and a narrowing net loss, underscoring how higher test volumes are helping to absorb the costs of research and commercialization. For investors, the balance between rapid top line expansion and the path toward profitability remains central.

Revenue up double digits

In its latest available quarterly report for Q1 2025, Natera reported total revenue of approximately $389 million, marking an increase of around 29% from roughly $302 million in Q1 2024. That comparison highlights how demand for the company’s genetic testing offerings is expanding year over year, with oncology and women’s health services contributing the bulk of the growth. The revenue trajectory has been supported by higher test volumes and the continued roll out of new indications across cancer detection and monitoring.

Alongside the revenue increase, Natera’s cost structure reflects the heavy investments typical of a high growth diagnostics business. Cost of revenue and operating expenses connected to research and development, sales, and general administration have risen in absolute terms, but the faster pace of revenue expansion has helped the company reduce its net loss as a percentage of sales. That dynamic is important for investors who track whether the business model can eventually deliver sustainable positive earnings while maintaining innovation and commercial momentum.

Loss narrows as volumes rise

For Q1 2025, Natera reported a net loss attributable to common stockholders of about $56 million, an improvement from a net loss of approximately $68 million in Q1 2024. The narrowing loss of roughly $12 million year over year signals that incremental gross profit from higher test volumes is partially offsetting the fixed and semi fixed components of the company’s cost base. Although the business remains loss making, the direction of change suggests that scale effects are gradually working through the income statement.

On a per share basis, this net loss translated into a basic and diluted loss per share figure that showed a smaller deficit than in the prior year period. That trend matters because many valuations in the diagnostics sector are based on expectations for eventual profitability rather than current earnings levels. A consistent pattern of improving losses, provided it is driven by operating leverage rather than one off items, can underpin confidence that management’s strategy is moving toward a more sustainable financial profile.

Genetic testing products and oncology focus

Natera derives its revenue primarily from genetic testing services used in oncology, women’s health, and organ health, where clinicians employ the company’s assays to detect and monitor disease through analysis of DNA fragments circulating in the blood. A representative oncology offering is a tumor informed test used to monitor minimal residual disease in cancer patients after surgery or systemic therapy. Over recent quarters, Natera has reported rising adoption of such oncology assays, and that segment has become a key driver of revenue growth as more healthcare providers integrate molecular residual disease monitoring into routine care.

The company also continues to generate significant revenue from prenatal screening and other reproductive health tests, which provide information on potential genetic conditions during pregnancy. While growth rates in the women’s health portfolio may differ from the faster rising oncology segment, the diversification across indications can help smooth the overall revenue profile. For investors, the mix between oncology, women’s health, and organ health is relevant because it influences long term margins, reimbursement dynamics, and competitive positioning in the broader diagnostics market.

Shares and market valuation context

Natera shares are listed on Nasdaq under the ticker symbol NTRA, giving investors access to the stock on a major US technology and healthcare oriented exchange. As of mid 2025, the company’s market capitalization stood in the region of $9 billion, based on a share price in the upper double digit dollar range and the number of outstanding shares reported in its filings. That valuation level reflects the market’s assessment of the growth potential in genetic testing and the prospects for the company to translate revenue expansion into positive free cash flow over time.

From a trading perspective, Natera stock has experienced meaningful swings over recent years, with the share price moving between a 52 week high above $90 and a 52 week low near $40 during one observed period. Such volatility is not unusual for high growth healthcare names, where sentiment can shift as clinical trial data, reimbursement decisions, or competitive developments emerge. For investors evaluating the stock, the combination of strong revenue growth, improving losses, and share price variability underscores the importance of aligning risk tolerance with the company’s stage of development.